<DOC>
	<DOCNO>NCT00407303</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogenic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell .</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Combination With Bortezomib Treatment Relapsed Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description>This multi-center , open-label , Phase I study Obatoclax administer combination bortezomib 3-week cycle patient relapse refractory Mantle Cell Lymphoma . Treatment may administer outpatient basis . No investigational commercial agent therapy describe herein may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result Mantle Cell Lymphoma allow .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Pathological confirmation Mantle Cell Lymphoma ( ML ) Must document relapse progression follow 1 2 prior line antineoplastic therapy Must normal organ function Must ability understand willingness sign write informed consent form No agent therapy administer intent treat malignancy Patients prior exposure obatoclax Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>